touchINFECTIOUSDISEASES met with Dr Joshua Parsons Cohen (Independent Healthcare Analyst, Healthcare Analytics, Boston, MA, USA) to discuss the persistence on guideline-recommended HIV treatment, and which treatment regimens were associated with the highest persistence.
The abstract entitled: ‘Persistence on guideline-recommended HIV treatment: Comparison among US Medicaid beneficiaries newly initiating treatment with single-versus multiple-tablet regimens’ was presented at the 18th European AIDS Conference (EACS 2021), 27-30 October, 2021.
Questions:
- Why is there a need for more persistence data on HIV treatment? (0:32)
- What were the aims and methodology of your study?  (1:20)
- Which treatment regimens were associated with the highest persistence? (2:47)
- What are the implications of these findings for future recommendations on antiretroviral therapy? (4:02)
- What were the limitations of this study, and what future studies are planned? (4:51)
Disclosures: Joshua P Cohen is involved in patient adherence to single versus multiple tablet regimens funded by Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of EACS (Hybrid) Conference 2021
